Recent News for ACRS - Aclaris Therapeutics, Inc.

Date Title
Apr 9 The Daily Biotech Pulse: Negative Regulatory Tidings For Provention Bio, Celcuity Soars On In-licensing Deal, 2 IPOs
Mar 23 The Daily Biotech Pulse: FDA Approvals For Merck, Pacira And Zealand, Roche-Regeneron Ace Late-Stage COVID-19 Study, AlloVir Appoints Gilead Virology Chief As CEO
Mar 18 Top Biotech Stocks for Q2 2021
Mar 16 Aclaris Therapeutics (ACRS) Presents At H.C. Wainwright Global Life Sciences Virtual Conference - Slideshow
Mar 15 Aclaris completes enrollment of mid-stage trial for atopic dermatitis
Mar 15 Aclaris Therapeutics Completes Enrollment in its Phase 2a Clinical Trial of ATI-1777 for Moderate to Severe Atopic Dermatitis
Mar 2 Aclaris Therapeutics: A Potential Big Pharma Deal May Be In The Horizon
Feb 25 Aclaris Therapeutics EPS misses by $0.04, beats on revenue
Feb 25 Aclaris Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides a Corporate Update
Feb 22 Aclaris Therapeutics stock spikes after speculation of potential sale
Feb 22 Aclaris Therapeutics to Participate in Upcoming Investor Conferences
Feb 10 Aclaris Therapeutics to Participate in the 10th Annual SVB Leerink Global Healthcare Conference
Jan 25 Gaining Ground After A Tough Couple Of Weeks
Jan 21 The Daily Biotech Pulse: Addex Jumps On Positive Data For Out-Licensed Drug, COVID-19 Vaccine Developer Inovio Announces $150M Follow-On Offering, Boston Scientific Goes Shopping
Jan 20 How High Is the Blue Sky for Aclaris Stock? Analyst Weighs In
Jan 20 Biotech Stock Roundup: ALXN Pauses Study, ACRS & GRTS Surge, & Other Updates
Jan 20 Aclaris (ACRS) Up on Preliminary Data for MK2 Inhibitor in RA
Jan 20 Aclaris shares rise 10% after pricing equity offering
Jan 20 Aclaris Announces Pricing of Public Offering of Common Stock
Jan 20 The Daily Biotech Pulse: FDA Greenlights Merck's Heart Failure Drug, Histogen Hit With Clinical Hold, Aptorum Gets Nod For Commencing Human Study
Jan 20 Aclaris Explodes 220% On ‘Positive Data’ From Rheumatoid Arthritis Trial
Jan 19 Aclaris Triples After Progress in Rheumatoid Arthritis Drug Trial
Jan 19 Aclaris Therapeutics readies proposed public offering
Jan 19 Aclaris Announces Proposed Public Offering of Common Stock
Jan 19 Mid-Afternoon Market Update: Nasdaq Surges 1.5%; Aclaris Therapeutics Shares Spike Higher
Back to the Main ACRS Page...